Trials / Completed
CompletedNCT02720692
Evaluation of N1539 Following Major Surgery
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety of N1539 Following Major Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 722 (actual)
- Sponsor
- Baudax Bio · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N1539 | |
| DRUG | Intravenous Placebo |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-03-01
- Completion
- 2017-05-01
- First posted
- 2016-03-28
- Last updated
- 2023-06-22
- Results posted
- 2023-05-25
Locations
32 sites across 4 countries: United States, Australia, Canada, New Zealand
Source: ClinicalTrials.gov record NCT02720692. Inclusion in this directory is not an endorsement.